|
 |
Obchodní název |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Camtoop |
Mexiko |
|
Cantop |
Indie |
|
Hycamtin |
äpanÏlsko, Austrálie, Belgie, BrazÌlie, Chile, Chorvatsko, Dánsko, Egypt, Finsko, Francie, Irsko, Island, Itálie, Japonsko, Kanada, Kolumbie, Lucembursko, Malajsie, MaÔarsko, NÏmecko, Nizozemsko, Norsko, Polsko, Portugalsko, Rakousko, Rumunsko, Saúdská Arábie, Spojené arabské emiráty, Švédsko, Švýcarsko, Turecko, USA, Velká Británie, Venezuela, ÿecko |
|
Oncotecan |
Ekvádor, Kolumbie |
|
Potactasol |
Argentina, Belgie, Chorvatsko, Finsko, Irsko, Itálie, MaÔarsko, NÏmecko, Norsko, Rumunsko, Slovinsko |
|
Topodria |
Kolumbie |
|
Topokebir |
Argentina |
|
Topotecan |
äpanÏlsko, Argentina, Belgie, BrazÌlie, Chile, Chorvatsko, Finsko, Francie, Irsko, Itálie, Kanada, Kolumbie, MaÔarsko, NÏmecko, Norsko, Peru, Rumunsko, Švédsko, Švýcarsko, Velká Británie |
|
Topotel |
Egypt |
|
Toranex |
Mexiko |
|
Tpopoxin |
Turecko |
|
|
 |
 |
Odkazy : Topotecan |
|
|
typ |
uveřejnění |
| 753 |
Laboratoř |
Topotecan (Topotecan Medac®) - Summary of Product Characteristics
Medac 2016 |
| 823 |
noviny |
Patel K, Craig SB, McBride MG, Palepu NR.
Microbial inhibitory properties and stability of topotecan hydrochloride injection.
Am J Health-Syst Pharm 1998 ; 55: 1584-1587. |
| 1026 |
noviny |
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881. |
| 1075 |
noviny |
Craig SB, Bhatt UH, Patel K.
Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers.
J Pharm Biomed Anal 1997 ; 16: 199-205. |
| 1274 |
noviny |
Krämer I, Thiesen J.
Pharmazeutische aspekte von topotecan-infusionen.
TAP Pharmazeutische Zeitung 1997 ; 31: 30-33. |
| 1423 |
noviny |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1425 |
noviny |
Krämer I, Thiesen J.
Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices.
J Oncol Pharm Practice 1999 ; 5: 75-82. |
| 1662 |
noviny |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1953 |
noviny |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1976 |
noviny |
Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241. |
| 5157 |
noviny |
Bello W, Hosotte C, Stampfli C, Pierrot A, Munier F L, Berger-Gryllaki M, Pezzatti J, Carrez L, Sadeghipour F.
Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery
EJHP 2025 33:67-72 |
|
|
